Click for best price
Long Acting Beta Agonist Market Size, Share 2024
| Market size in 2024 |
US$ 2.34 billion
|
Forecast Market size by 2030 |
US$ 3.12 billion
|
| Growth Rate |
CAGR of 4.9% |
Number of Pages |
115 Pages |
The global Long Acting Beta Agonist market size was valued at US$ 2.34 billion in 2024 and is projected to reach US$ 3.12 billion by 2030, at a CAGR of 4.9% during the forecast period 2024-2030.
United States Long Acting Beta Agonist market size was valued at US$ 678.9 million in 2024 and is projected to reach US$ 889.4 million by 2030, at a CAGR of 4.6% during the forecast period 2024-2030.
Report Overview
Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.
This report provides a deep insight into the global Long Acting Beta Agonist market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Long Acting Beta Agonist Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Long Acting Beta Agonist market in any manner.
Global Long Acting Beta Agonist Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Sumitomo Dainippon Pharma
- AstraZeneca
- GlaxoSmithKline
- Boehringer Ingelheim International
- Mylan
- Teva
- Merck
Market Segmentation (by Type)
Market Segmentation (by Application)
- Hospitals
- Clinics
- Ambulatory Surgical Center
- Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Long Acting Beta Agonist Market
- Overview of the regional outlook of the Long Acting Beta Agonist Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
| Report Attributes |
Report Details |
| Report Title |
Global Long Acting Beta Agonist Market Research Report 2024(Status and Outlook) |
| Market size in 2024 |
US$ 2.34 billion
|
| Forecast Market size by 2030 |
US$ 3.12 billion
|
| Growth Rate |
CAGR of 4.9% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
115 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Long Acting Beta Agonist
1.2 Key Market Segments
1.2.1 Long Acting Beta Agonist Segment by Type
1.2.2 Long Acting Beta Agonist Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Long Acting Beta Agonist Market Overview
2.1 Global Market Overview
2.1.1 Global Long Acting Beta Agonist Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Long Acting Beta Agonist Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Long Acting Beta Agonist Market Competitive Landscape
3.1 Global Long Acting Beta Agonist Sales by Manufacturers (2019-2024)
3.2 Global Long Acting Beta Agonist Revenue Market Share by Manufacturers (2019-2024)
3.3 Long Acting Beta Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Long Acting Beta Agonist Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Long Acting Beta Agonist Sales Sites, Area Served, Product Type
3.6 Long Acting Beta Agonist Market Competitive Situation and Trends
3.6.1 Long Acting Beta Agonist Market Concentration Rate
3.6.2 Global 5 and 10 Largest Long Acting Beta Agonist Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Long Acting Beta Agonist Industry Chain Analysis
4.1 Long Acting Beta Agonist Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Long Acting Beta Agonist Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Long Acting Beta Agonist Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Long Acting Beta Agonist Sales Market Share by Type (2019-2024)
6.3 Global Long Acting Beta Agonist Market Size Market Share by Type (2019-2024)
6.4 Global Long Acting Beta Agonist Price by Type (2019-2024)
7 Long Acting Beta Agonist Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Long Acting Beta Agonist Market Sales by Application (2019-2024)
7.3 Global Long Acting Beta Agonist Market Size (M USD) by Application (2019-2024)
7.4 Global Long Acting Beta Agonist Sales Growth Rate by Application (2019-2024)
8 Long Acting Beta Agonist Market Segmentation by Region
8.1 Global Long Acting Beta Agonist Sales by Region
8.1.1 Global Long Acting Beta Agonist Sales by Region
8.1.2 Global Long Acting Beta Agonist Sales Market Share by Region
8.2 North America
8.2.1 North America Long Acting Beta Agonist Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Long Acting Beta Agonist Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Long Acting Beta Agonist Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Long Acting Beta Agonist Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Long Acting Beta Agonist Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Sumitomo Dainippon Pharma
9.1.1 Sumitomo Dainippon Pharma Long Acting Beta Agonist Basic Information
9.1.2 Sumitomo Dainippon Pharma Long Acting Beta Agonist Product Overview
9.1.3 Sumitomo Dainippon Pharma Long Acting Beta Agonist Product Market Performance
9.1.4 Sumitomo Dainippon Pharma Business Overview
9.1.5 Sumitomo Dainippon Pharma Long Acting Beta Agonist SWOT Analysis
9.1.6 Sumitomo Dainippon Pharma Recent Developments
9.2 AstraZeneca
9.2.1 AstraZeneca Long Acting Beta Agonist Basic Information
9.2.2 AstraZeneca Long Acting Beta Agonist Product Overview
9.2.3 AstraZeneca Long Acting Beta Agonist Product Market Performance
9.2.4 AstraZeneca Business Overview
9.2.5 AstraZeneca Long Acting Beta Agonist SWOT Analysis
9.2.6 AstraZeneca Recent Developments
9.3 GlaxoSmithKline
9.3.1 GlaxoSmithKline Long Acting Beta Agonist Basic Information
9.3.2 GlaxoSmithKline Long Acting Beta Agonist Product Overview
9.3.3 GlaxoSmithKline Long Acting Beta Agonist Product Market Performance
9.3.4 GlaxoSmithKline Long Acting Beta Agonist SWOT Analysis
9.3.5 GlaxoSmithKline Business Overview
9.3.6 GlaxoSmithKline Recent Developments
9.4 Boehringer Ingelheim International
9.4.1 Boehringer Ingelheim International Long Acting Beta Agonist Basic Information
9.4.2 Boehringer Ingelheim International Long Acting Beta Agonist Product Overview
9.4.3 Boehringer Ingelheim International Long Acting Beta Agonist Product Market Performance
9.4.4 Boehringer Ingelheim International Business Overview
9.4.5 Boehringer Ingelheim International Recent Developments
9.5 Mylan
9.5.1 Mylan Long Acting Beta Agonist Basic Information
9.5.2 Mylan Long Acting Beta Agonist Product Overview
9.5.3 Mylan Long Acting Beta Agonist Product Market Performance
9.5.4 Mylan Business Overview
9.5.5 Mylan Recent Developments
9.6 Teva
9.6.1 Teva Long Acting Beta Agonist Basic Information
9.6.2 Teva Long Acting Beta Agonist Product Overview
9.6.3 Teva Long Acting Beta Agonist Product Market Performance
9.6.4 Teva Business Overview
9.6.5 Teva Recent Developments
9.7 Merck
9.7.1 Merck Long Acting Beta Agonist Basic Information
9.7.2 Merck Long Acting Beta Agonist Product Overview
9.7.3 Merck Long Acting Beta Agonist Product Market Performance
9.7.4 Merck Business Overview
9.7.5 Merck Recent Developments
10 Long Acting Beta Agonist Market Forecast by Region
10.1 Global Long Acting Beta Agonist Market Size Forecast
10.2 Global Long Acting Beta Agonist Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Long Acting Beta Agonist Market Size Forecast by Country
10.2.3 Asia Pacific Long Acting Beta Agonist Market Size Forecast by Region
10.2.4 South America Long Acting Beta Agonist Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Long Acting Beta Agonist by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Long Acting Beta Agonist Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Long Acting Beta Agonist by Type (2025-2030)
11.1.2 Global Long Acting Beta Agonist Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Long Acting Beta Agonist by Type (2025-2030)
11.2 Global Long Acting Beta Agonist Market Forecast by Application (2025-2030)
11.2.1 Global Long Acting Beta Agonist Sales (K Units) Forecast by Application
11.2.2 Global Long Acting Beta Agonist Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Long Acting Beta Agonist Market Size Comparison by Region (M USD)
Table 5. Global Long Acting Beta Agonist Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Long Acting Beta Agonist Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Long Acting Beta Agonist Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Long Acting Beta Agonist Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long Acting Beta Agonist as of 2022)
Table 10. Global Market Long Acting Beta Agonist Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Long Acting Beta Agonist Sales Sites and Area Served
Table 12. Manufacturers Long Acting Beta Agonist Product Type
Table 13. Global Long Acting Beta Agonist Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Long Acting Beta Agonist
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Long Acting Beta Agonist Market Challenges
Table 22. Global Long Acting Beta Agonist Sales by Type (K Units)
Table 23. Global Long Acting Beta Agonist Market Size by Type (M USD)
Table 24. Global Long Acting Beta Agonist Sales (K Units) by Type (2019-2024)
Table 25. Global Long Acting Beta Agonist Sales Market Share by Type (2019-2024)
Table 26. Global Long Acting Beta Agonist Market Size (M USD) by Type (2019-2024)
Table 27. Global Long Acting Beta Agonist Market Size Share by Type (2019-2024)
Table 28. Global Long Acting Beta Agonist Price (USD/Unit) by Type (2019-2024)
Table 29. Global Long Acting Beta Agonist Sales (K Units) by Application
Table 30. Global Long Acting Beta Agonist Market Size by Application
Table 31. Global Long Acting Beta Agonist Sales by Application (2019-2024) & (K Units)
Table 32. Global Long Acting Beta Agonist Sales Market Share by Application (2019-2024)
Table 33. Global Long Acting Beta Agonist Sales by Application (2019-2024) & (M USD)
Table 34. Global Long Acting Beta Agonist Market Share by Application (2019-2024)
Table 35. Global Long Acting Beta Agonist Sales Growth Rate by Application (2019-2024)
Table 36. Global Long Acting Beta Agonist Sales by Region (2019-2024) & (K Units)
Table 37. Global Long Acting Beta Agonist Sales Market Share by Region (2019-2024)
Table 38. North America Long Acting Beta Agonist Sales by Country (2019-2024) & (K Units)
Table 39. Europe Long Acting Beta Agonist Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Long Acting Beta Agonist Sales by Region (2019-2024) & (K Units)
Table 41. South America Long Acting Beta Agonist Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Long Acting Beta Agonist Sales by Region (2019-2024) & (K Units)
Table 43. Sumitomo Dainippon Pharma Long Acting Beta Agonist Basic Information
Table 44. Sumitomo Dainippon Pharma Long Acting Beta Agonist Product Overview
Table 45. Sumitomo Dainippon Pharma Long Acting Beta Agonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Sumitomo Dainippon Pharma Business Overview
Table 47. Sumitomo Dainippon Pharma Long Acting Beta Agonist SWOT Analysis
Table 48. Sumitomo Dainippon Pharma Recent Developments
Table 49. AstraZeneca Long Acting Beta Agonist Basic Information
Table 50. AstraZeneca Long Acting Beta Agonist Product Overview
Table 51. AstraZeneca Long Acting Beta Agonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. AstraZeneca Business Overview
Table 53. AstraZeneca Long Acting Beta Agonist SWOT Analysis
Table 54. AstraZeneca Recent Developments
Table 55. GlaxoSmithKline Long Acting Beta Agonist Basic Information
Table 56. GlaxoSmithKline Long Acting Beta Agonist Product Overview
Table 57. GlaxoSmithKline Long Acting Beta Agonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. GlaxoSmithKline Long Acting Beta Agonist SWOT Analysis
Table 59. GlaxoSmithKline Business Overview
Table 60. GlaxoSmithKline Recent Developments
Table 61. Boehringer Ingelheim International Long Acting Beta Agonist Basic Information
Table 62. Boehringer Ingelheim International Long Acting Beta Agonist Product Overview
Table 63. Boehringer Ingelheim International Long Acting Beta Agonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Boehringer Ingelheim International Business Overview
Table 65. Boehringer Ingelheim International Recent Developments
Table 66. Mylan Long Acting Beta Agonist Basic Information
Table 67. Mylan Long Acting Beta Agonist Product Overview
Table 68. Mylan Long Acting Beta Agonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Mylan Business Overview
Table 70. Mylan Recent Developments
Table 71. Teva Long Acting Beta Agonist Basic Information
Table 72. Teva Long Acting Beta Agonist Product Overview
Table 73. Teva Long Acting Beta Agonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Teva Business Overview
Table 75. Teva Recent Developments
Table 76. Merck Long Acting Beta Agonist Basic Information
Table 77. Merck Long Acting Beta Agonist Product Overview
Table 78. Merck Long Acting Beta Agonist Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Merck Business Overview
Table 80. Merck Recent Developments
Table 81. Global Long Acting Beta Agonist Sales Forecast by Region (2025-2030) & (K Units)
Table 82. Global Long Acting Beta Agonist Market Size Forecast by Region (2025-2030) & (M USD)
Table 83. North America Long Acting Beta Agonist Sales Forecast by Country (2025-2030) & (K Units)
Table 84. North America Long Acting Beta Agonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 85. Europe Long Acting Beta Agonist Sales Forecast by Country (2025-2030) & (K Units)
Table 86. Europe Long Acting Beta Agonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 87. Asia Pacific Long Acting Beta Agonist Sales Forecast by Region (2025-2030) & (K Units)
Table 88. Asia Pacific Long Acting Beta Agonist Market Size Forecast by Region (2025-2030) & (M USD)
Table 89. South America Long Acting Beta Agonist Sales Forecast by Country (2025-2030) & (K Units)
Table 90. South America Long Acting Beta Agonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 91. Middle East and Africa Long Acting Beta Agonist Consumption Forecast by Country (2025-2030) & (Units)
Table 92. Middle East and Africa Long Acting Beta Agonist Market Size Forecast by Country (2025-2030) & (M USD)
Table 93. Global Long Acting Beta Agonist Sales Forecast by Type (2025-2030) & (K Units)
Table 94. Global Long Acting Beta Agonist Market Size Forecast by Type (2025-2030) & (M USD)
Table 95. Global Long Acting Beta Agonist Price Forecast by Type (2025-2030) & (USD/Unit)
Table 96. Global Long Acting Beta Agonist Sales (K Units) Forecast by Application (2025-2030)
Table 97. Global Long Acting Beta Agonist Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Long Acting Beta Agonist
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Long Acting Beta Agonist Market Size (M USD), 2019-2030
Figure 5. Global Long Acting Beta Agonist Market Size (M USD) (2019-2030)
Figure 6. Global Long Acting Beta Agonist Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Long Acting Beta Agonist Market Size by Country (M USD)
Figure 11. Long Acting Beta Agonist Sales Share by Manufacturers in 2023
Figure 12. Global Long Acting Beta Agonist Revenue Share by Manufacturers in 2023
Figure 13. Long Acting Beta Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Long Acting Beta Agonist Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Long Acting Beta Agonist Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Long Acting Beta Agonist Market Share by Type
Figure 18. Sales Market Share of Long Acting Beta Agonist by Type (2019-2024)
Figure 19. Sales Market Share of Long Acting Beta Agonist by Type in 2023
Figure 20. Market Size Share of Long Acting Beta Agonist by Type (2019-2024)
Figure 21. Market Size Market Share of Long Acting Beta Agonist by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Long Acting Beta Agonist Market Share by Application
Figure 24. Global Long Acting Beta Agonist Sales Market Share by Application (2019-2024)
Figure 25. Global Long Acting Beta Agonist Sales Market Share by Application in 2023
Figure 26. Global Long Acting Beta Agonist Market Share by Application (2019-2024)
Figure 27. Global Long Acting Beta Agonist Market Share by Application in 2023
Figure 28. Global Long Acting Beta Agonist Sales Growth Rate by Application (2019-2024)
Figure 29. Global Long Acting Beta Agonist Sales Market Share by Region (2019-2024)
Figure 30. North America Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Long Acting Beta Agonist Sales Market Share by Country in 2023
Figure 32. U.S. Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Long Acting Beta Agonist Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Long Acting Beta Agonist Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Long Acting Beta Agonist Sales Market Share by Country in 2023
Figure 37. Germany Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Long Acting Beta Agonist Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Long Acting Beta Agonist Sales Market Share by Region in 2023
Figure 44. China Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Long Acting Beta Agonist Sales and Growth Rate (K Units)
Figure 50. South America Long Acting Beta Agonist Sales Market Share by Country in 2023
Figure 51. Brazil Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Long Acting Beta Agonist Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Long Acting Beta Agonist Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Long Acting Beta Agonist Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Long Acting Beta Agonist Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Long Acting Beta Agonist Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Long Acting Beta Agonist Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Long Acting Beta Agonist Market Share Forecast by Type (2025-2030)
Figure 65. Global Long Acting Beta Agonist Sales Forecast by Application (2025-2030)
Figure 66. Global Long Acting Beta Agonist Market Share Forecast by Application (2025-2030)
